Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 173,493 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 173,493 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $18.15, for a total transaction of $3,148,897.95. Following the completion of the transaction, the director directly owned 9,682 shares of the company’s stock, valued at $175,728.30. This trade represents a 94.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Performance

DYN stock opened at $18.04 on Tuesday. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. The firm has a market cap of $2.98 billion, a PE ratio of -5.10 and a beta of 1.29. The business’s 50-day moving average price is $17.74 and its two-hundred day moving average price is $18.49.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.02). As a group, research analysts forecast that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DYN shares. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. HC Wainwright reduced their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Finally, Chardan Capital reissued a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Creative Planning increased its stake in shares of Dyne Therapeutics by 6.8% during the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after purchasing an additional 1,109 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics in the 1st quarter valued at about $26,000. Caxton Associates LLP grew its holdings in Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after purchasing an additional 1,627 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in Dyne Therapeutics by 9.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock worth $315,000 after buying an additional 2,108 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.